D. Wu , L. Chen , W. Liao , Y. Ding , Q. Zhang , Z. Li , L. Liu
{"title":"Fascin1 expression predicts poor prognosis in patients with nasopharyngeal carcinoma and correlates with tumor invasion","authors":"D. Wu , L. Chen , W. Liao , Y. Ding , Q. Zhang , Z. Li , L. Liu","doi":"10.1093/annonc/mdp333","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The purpose of this study was to investigate prognostic significance of fascin1 in nasopharyngeal carcinoma (NPC) and evaluate the association of fascin1 with tumor invasion.</p></div><div><h3>Materials and methods</h3><p>Immunohistochemical staining for fascin1 was carried out on paraffin-embedded tissue sections from 161 patients with NPC. Data were subjected to statistical analysis with respect to clinicopathological variables and survival. Small interfering RNA (siRNA) approach was used to knockdown fascin1 expression in NPC cells to determine whether fascin1 contributes to tumor cell invasion.</p></div><div><h3>Results</h3><p>Immunohistochemical analysis showed that fascin1 was highly expressed in 95 (59.0%) of 161 paraffin-embedded NPC tissues. Fascin1 expression was significantly correlated with clinical stage (<em>P</em> <!--><<!--> <!-->0.001) and N classification (<em>P</em> <!--><<!--> <!-->0.001). Statistical analysis showed that fascin1 expression was inversely correlated with both overall and disease-free survival of NPC patients. Multivariate analysis showed that fascin1 expression was an independent prognostic indicator for patient's survival. Moreover, disruption of endogenous fascin1 expression in NPC cells using siRNA technique suppressed NPC cell invasiveness and decreased cell filopodia and lamellopodia.</p></div><div><h3>Conclusion</h3><p>The present study indicates that fascin1 expression is inversely correlated with NPC patient survival and directly correlated with the malignant status of NPC.</p></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"21 3","pages":"Pages 589-596"},"PeriodicalIF":65.4000,"publicationDate":"2010-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/annonc/mdp333","citationCount":"24","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0923753419382961","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 24
Abstract
Background
The purpose of this study was to investigate prognostic significance of fascin1 in nasopharyngeal carcinoma (NPC) and evaluate the association of fascin1 with tumor invasion.
Materials and methods
Immunohistochemical staining for fascin1 was carried out on paraffin-embedded tissue sections from 161 patients with NPC. Data were subjected to statistical analysis with respect to clinicopathological variables and survival. Small interfering RNA (siRNA) approach was used to knockdown fascin1 expression in NPC cells to determine whether fascin1 contributes to tumor cell invasion.
Results
Immunohistochemical analysis showed that fascin1 was highly expressed in 95 (59.0%) of 161 paraffin-embedded NPC tissues. Fascin1 expression was significantly correlated with clinical stage (P < 0.001) and N classification (P < 0.001). Statistical analysis showed that fascin1 expression was inversely correlated with both overall and disease-free survival of NPC patients. Multivariate analysis showed that fascin1 expression was an independent prognostic indicator for patient's survival. Moreover, disruption of endogenous fascin1 expression in NPC cells using siRNA technique suppressed NPC cell invasiveness and decreased cell filopodia and lamellopodia.
Conclusion
The present study indicates that fascin1 expression is inversely correlated with NPC patient survival and directly correlated with the malignant status of NPC.
期刊介绍:
Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, offers rapid and efficient peer-reviewed publications on innovative cancer treatments and translational research in oncology and precision medicine.
The journal primarily focuses on areas such as systemic anticancer therapy, with a specific emphasis on molecular targeted agents and new immune therapies. We also welcome randomized trials, including negative results, as well as top-level guidelines. Additionally, we encourage submissions in emerging fields that are crucial to personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Manuscripts related to radiotherapy, surgery, and pediatrics will be considered if they demonstrate a clear interaction with any of the aforementioned fields or if they present groundbreaking findings.
Our international editorial board comprises renowned experts who are leaders in their respective fields. Through Annals of Oncology, we strive to provide the most effective communication on the dynamic and ever-evolving global oncology landscape.